Annovis Bio, Inc. (ANVS) Insider Trading & SEC Filings
Last SEC filing
Annovis Bio, Inc. (ANVS) has filed 1 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-05-22. Insiders disclosed 3 open-market purchases totaling $143K. 4 Form 8-K material event filings were reported by ANVS in the last 90 days. InsiderAlpha tracks every ANVS SEC filing - Form 4, Form 144, and 8-K - in real time, including Rule 10b5-1 plan detection.
About Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc. trades under the ticker ANVS. InsiderAlpha tracks 12 primary SEC Form 4 filings from 3 reporting insiders for ANVS since 2025, sourced directly from SEC EDGAR.
| Sector | Health Care insider trading |
|---|---|
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
| SEC CIK | 0001477845 |
90-Day SEC Filing Activity
| Insider purchases (90d) | 3 ($143K) |
|---|---|
| Form 4 filings (90d) | 1 |
| Form 8-K filings (90d) | 4 |
| Latest Form 4 filing | 2026-05-22 |
Recent ANVS Insider Transactions (Form 4)
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Michael B. Hoffman | Director | P - Open-market purchase | 54.9K | $1.90 | $104K | SEC | |
| Michael B. Hoffman | Director | P - Open-market purchase | 18.8K | $1.80 | $34K | SEC | |
| Michael B. Hoffman | Director | P - Open-market purchase | 2.6K | $1.75 | $4K | SEC | |
| Michael B. Hoffman | Director | P - Open-market purchase | 713.8K | $2.10 | $1.50M | SEC | |
| Michael B. Hoffman | Director | P - Open-market purchase | 1.5K | $4.13 | $6K | SEC | |
| Michael B. Hoffman | Director | P - Open-market purchase | 9.2K | $3.85 | $35K | SEC | |
| Michael B. Hoffman | Director | P - Open-market purchase | 415 | $4.14 | $2K | SEC | |
| Michael B. Hoffman | Director | P - Open-market purchase | 28.1K | $4.15 | $117K | SEC | |
| Michael B. Hoffman | Director | P - Open-market purchase | 10.0K | $3.49 | $35K | SEC | |
| Michael B. Hoffman | Director | P - Open-market purchase | 10.0K | $3.50 | $35K | SEC | |
| Michael B. Hoffman | Director | P - Open-market purchase | 15.0K | $2.11 | $32K | SEC | |
| Maria-Luisa Maccecchini | President & CEO | P - Open-market purchase | 97.6K | $2.05 | $200K | SEC | |
| Michael B. Hoffman | Director | P - Open-market purchase | 975.6K | $2.05 | $2.00M | SEC | |
| Claudine Bruck | Director | M - Option exercise | 7.1K | $0.14 | $1,000 | SEC | |
| Michael B. Hoffman | Director | A - Grant or award | 5.0K | $2.30 | $12K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Annovis Bio, Inc. (ANVS). Updated in real time as new filings are submitted to the SEC.
Most-Active ANVS Insiders - Last 90 Days
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Michael B. Hoffman | 3 | $143K |
Recent ANVS Form 8-K Material Events
- - Item 8.01, 9.01 [SEC]
- - Item 5.07, 9.01 [SEC]
- - Item 1.01, 7.01, 9.01 [SEC]
- - Item 2.02, 9.01 [SEC]
- - Item 1.01, 7.01, 9.01 · Financing · neutral [SEC]
Annovis Bio entered into an underwriting agreement on April 9, 2026 to conduct a registered direct offering of 5,263,156 shares of common stock and accompanying warrants at a combined price of $1.90 per share, expected to raise approximately $10 million in gross proceeds. The com
Recent Insider Filings
- - Michael B. Hoffman (Director)
- - Michael B. Hoffman (Director)
- - Michael B. Hoffman (Director)
- - Michael B. Hoffman (Director)
- - Michael B. Hoffman (Director)
Form 4 Transaction Code Reference
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in ANVS insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
ANVS Insider Trading - FAQ
- What is the latest insider trade for ANVS?
- Annovis Bio, Inc. (ANVS) had 1 insider filings in the last 90 days, with the most recent on 2026-05-22. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
- How many insiders are buying ANVS stock?
- 3 insider purchases of ANVS were filed in the last 90 days, totaling $143K.
- How many insiders are selling ANVS stock?
- 0 insider sales of ANVS were filed in the last 90 days.
- Where can I see ANVS SEC filings (Form 4, 10-K, 10-Q, 8-K)?
- This page tracks ANVS Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care Companies with Insider Activity
Other companies in the InsiderAlpha index with a significant SEC Form 4 insider-trading footprint:
- $APGE Apogee Therapeutics, Inc.
- $APVO Aptevo Therapeutics Inc.
- $ARTL ARTELO BIOSCIENCES, INC.
- $ARTV Artiva Biotherapeutics, Inc.
- $ASMB ASSEMBLY BIOSCIENCES, INC.
- $ATAI ATAI Life Sciences N.V.
- $AUPH Aurinia Pharmaceuticals Inc.
- $AWHL Aspira Women's Health Inc.
- $BAX BAXTER INTERNATIONAL INC
- $BCAX Bicara Therapeutics Inc.
Related Companies - Recent Insider Activity
- UNITED THERAPEUTICS Corp (UTHR)
- Liquidia Corp (LQDA)
- BeOne Medicines Ltd. (ONC)
- PERRIGO Co plc (PRGO)
- Processa Pharmaceuticals, Inc. (PCSA)
- Nuvalent, Inc. (NUVL)
- CYTOKINETICS INC (CYTK)
- Elanco Animal Health Inc (ELAN)
- Avalo Therapeutics, Inc. (AVTX)
- NATURES SUNSHINE PRODUCTS INC (NATR)
Learn More
- What is SEC Form 4?
- How to read insider buying signals
- Rule 10b5-1 trading plans explained
- The cluster buying signal
Open the live ANVS dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.